Theme
GLP-1 drugs moved from diabetes to obesity to a list of indications that keeps growing. This theme follows the makers, the fast followers and the businesses whose demand curves the drugs quietly bend.
What the theme is made of.
Calls on its names, and commentary on them with no call.
Who publishes here most. No ranking, no score.
The deflation that defined this industry has stopped in the categories that matter to this company.
Three launches land inside eighteen months with limited competition on two of them. The market still prices this as a levered generics business.
The trial reads out on a known date and the current price ascribes almost nothing to it. The asymmetry is the position, not the probability.
Three launches land inside eighteen months with limited competition on two of them. The market still prices this as a levered generics business.